Malignant Female Reproductive System Neoplasm

Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,463
Recruiting: 820
Ph III recruiting: 96
Growth YoY: +6.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (740)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03393962	Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors	enrolling by invitation	Phase 1 / Phase 2	20	Shenzhen Geno-Immune Medical InstituteOTHER	1	Jun 23, 2026	clinicaltrials
NCT07218003	A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4	enrolling by invitation	Phase 1	149	Rondo TherapeuticsINDUSTRY	1	Jun 11, 2026